These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2007-001715-36 A Multicenter, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute IV Infusion for Postoperative Ileus to Sub... 2008-07-13 due-trials
Not reported 2007-003279-38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute I.V. Infusion to Subjects with Severe Gast... 2009-01-20 due-trials
Not reported 2008-007226-19 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Ga... 2010-05-27 due-trials
Not reported 2010-023228-26 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointes... 2012-01-09 due-trials
Listed as ongoing, but also has a completion date 2010-023229-38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointes... 2012-03-29 bad-data
Not reported 2011-002594-33 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP 102 for the Treatment of Symptoms Associated with... 2012-11-19 due-trials
Not reported 2012-002576-14 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated w... 2012-12-17 due-trials